Precigen Inc. Reports Q1 2025 Net Loss of $54.2M; EPS Drops to $(0.18) Amid Increased Warrant Liabilities

Reuters
05/15
<a href="https://laohu8.com/S/PGEN">Precigen</a> Inc. Reports Q1 2025 Net Loss of $54.2M; EPS Drops to $(0.18) Amid Increased Warrant Liabilities

Precigen Inc., a biopharmaceutical company, reported its financial results for the first quarter of 2025, highlighting a significant shift in its financial metrics. The company experienced a change in total other income (expense), net, which shifted from an income of $0.6 million in the first quarter of 2024 to an expense of $31.6 million in the same period in 2025. This shift was primarily due to a $32.5 million increase in the fair value of warrant liabilities, influenced by a rise in Precigen's stock price and an increase in the liability related to additional warrants from paid-in-kind dividends of Series A Preferred Stock. This was partially offset by a $0.3 million increase in interest income due to higher investment balances. Precigen reported a net loss of $54.2 million, compared to a net loss of $23.7 million in the first quarter of 2024. The non-cash change in the fair value of warrant liabilities decreased the basic and diluted earnings per share by $0.11 in the first quarter of 2025. Additionally, the company ended the quarter with $81 million in cash, cash equivalents, and investments. Precigen's CFO, Harry Thomasian Jr., stated that this cash position is expected to fund operations into 2026, even considering a potential commercial launch of PRGN-2012 later in 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY86200) on May 14, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10